PeptideDB
es
EnglishEspañolDeutschPortuguês
PéptidosCategoríasCompararGuíasGlosario

Cerebrolysin

Bien estudiado

Neuropeptide Preparation | Neurological Recovery

CognitivoLongevidad

Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive

Datos moleculares y de investigación

Secuencia
Bioactive peptide mixture
Peso molecular
Variable
Vida media
Minutes (component-dependent; e.g., BDNF ~10 min)
Rutas (investigación)
injectable
Almacenamiento
Room temperature ≤25°C, protected from light in original carton - never freeze

Overview

Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.

Mechanism of action

IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.

Key research findings

  • Direct brain delivery
  • Standardized dosing
  • Extensive clinical evidence
  • Ready-to-use formulation
  • Used clinically in 50+ countries

Research applications

Cognitive

  • Alzheimer’s Disease — Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
  • Vascular Dementia — Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
  • Post-Stroke Cognitive Recovery — Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.

Neuroprotection

  • Acute Stroke — Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
  • Traumatic Brain Injury — Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
  • Subarachnoid Hemorrhage — Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.

Recovery

  • Motor Function Recovery — Some studies show enhanced recovery; results vary significantly between trials.
  • Neurological Function — Early administration within 72 hours shows better outcomes than delayed treatment.

Preguntas frecuentes sobre Cerebrolysin

Does Cerebrolysin actually work for stroke recovery or is the evidence mixed?+

Evidence is mixed. Large meta-analysis of 1,879 stroke patients showed NIHSS (neurological function) superiority, but an independent analysis found no significant improvement in modified Rankin Scale (functional outcomes). Cerebrolysin appears to have early neurological benefits without clear long-term functional recovery advantage.

Is Cerebrolysin safe given some published studies have been retracted?+

Yes, several Cerebrolysin studies were retracted due to research misconduct. However, well-conducted meta-analyses by independent researchers confirm safety and modest efficacy signals. Rely on meta-analyses and well-designed RCTs rather than individual studies, some of which have credibility issues.

How quickly should Cerebrolysin be started after stroke or TBI for best results?+

Early administration within 72 hours shows better outcomes than delayed treatment. Acute stroke protocols use 20-50mL daily IV infusion for 10-21 days. TBI protocols use similar dosing for 7-30 days depending on severity. Earlier initiation appears critical for neuroprotective benefit.

Can I mix Cerebrolysin with other IV solutions, vitamins, or medications?+

No. Official guidelines contraindicate mixing Cerebrolysin with amino acid solutions, cardiovascular medications, or vitamin solutions in the same IV infusion. Compatibility issues exist, so use dedicated IV lines. Flush with sodium chloride before and after administration per protocol.

References

  1. [1]Efficacy and Safety of Cerebrolysin in Neurorecovery After Moderate-Severe Traumatic Brain Injury: Results from the CAPTAIN II TrialNeurological Sciences
  2. [2]Safety and Efficacy of Cerebrolysin in Early Post-Stroke Recovery: A Meta-Analysis of Nine Randomized Clinical TrialsNeurological Sciences
  3. [3]Cerebrolysin for Functional Recovery in Patients with Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsInternational Journal of Neuroscience
  4. [4]Cerebrolysin in Patients with TBI: Systematic Review and Meta-AnalysisBrain Sciences
  5. [5]Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical TrialsDementia and Geriatric Cognitive Disorders
  6. [6]Cerebrolysin After Moderate to Severe Traumatic Brain Injury: Prospective Meta-Analysis of the CAPTAIN Trial SeriesNeurological Sciences
  7. [7]Cerebrolysin in Patients Diagnosed with Subarachnoid Hemorrhage: Observational Cohort StudyBrain Sciences
  8. [8]The Possible Role of Cerebrolysin in the Management of Vascular Dementia: Leveraging ConceptsNeuroscience

Péptidos relacionados

Adalank

Emerging research

N-Acetyl Selank Amidate | Enhanced Tuftsin Analog

Enhanced derivative of Selank with improved stability, blood-brain barrier penetration, and extended half-life compared to parent compound. Parent compound Selank approved in Russia since early 2000s.

CognitivoLongevidad

Adamax

Emerging research

Next-Generation Semax Derivative | Nootropic Neuropeptide

Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement,

CognitivoLongevidad

Cortagen

Moderate research

AEDP | Brain Cortex Bioregulator Peptide

Cortagen is a Khavinson bioregulator tetrapeptide (AEDP) with primary effects on the brain and central nervous system. Developed at Russia's St.

CognitivoLongevidad

Cyclic Glycine-Proline

Moderate research

IGF-1 Bioavailability Regulator & Neuroprotective Peptide

Endogenous cyclic dipeptide found in plasma, breast milk, and cerebrospinal fluid. Functions as metabolite of IGF-1, regulating its bioavailability through competitive binding to IGFBP-3.

CognitivoLongevidad